Skip to content
★ Sign in to follow
AA

Andrew A. Protter

Executive
Medivation, Inc.
Total declarations
6
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (3 ops.)
€495k

Latest filing published 10 Sept 2008 for MEDIVATION, INC., €4,194.

Insider track record

Disclosed buys
0
Disclosed sells
3
Signal history

No signal scores available.

Andrew A. Protter: trading record in brief

Andrew A. Protter discloses dealings in Medivation, Inc. to SEC (Form 4). Between 29 August 2008 and 3 September 2008, the trades on record add up to 6 filings.

Every open-market trade on record is a sale: 3 sales worth €495k. Besides market trades, the filings include 3 option exercises.

Most recently, on 10 September 2008, the filings show an option exercise worth €4,194 in Medivation, Inc. Filings reach the SEC (Form 4) feed a median of 8 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Andrew A. Protter

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total
  • ◇
    VP, Preclinical DevelopmentExecutivesMedivation, Inc.
    6,153 USD0SEC
    1,150 shares@ US$5.35Common StockSEC:0001181431-08-052351:0
  • ▼
    VP, Preclinical DevelopmentExecutivesMedivation, Inc.
    28,750 USD0SEC
    1,150 shares@ US$25.00Common StockSEC:0001181431-08-052351:1
  • ◇
    VP, Preclinical DevelopmentExecutivesMedivation, Inc.
    36,648 USD0SEC
    6,850 shares@ US$5.35Common StockSEC:0001181431-08-052351:2
  • ▼
    VP, Preclinical DevelopmentExecutivesMedivation, Inc.
    171,250 USD0SEC
    6,850 shares@ US$25.00Common StockSEC:0001181431-08-052351:3
  • ◇
    VP, Preclinical DevelopmentExecutivesMedivation, Inc.
    85,600 USD0SEC
    16,000 shares@ US$5.35Common StockSEC:0001181431-08-052351:4
  • ▼
    VP, Preclinical DevelopmentExecutivesMedivation, Inc.
    509,600 USD0SEC
    16,000 shares@ US$31.85Common StockSEC:0001181431-08-052351:5

6 of 6 declarations